Answers are grounded in this paper and cite their sources.
Our analysis failed to support application of TMB-H as a biomarker for treatment with ICB in all solid cancer types. Further tumor type-specific studies are warranted.
No takes yet. Share an insight, caveat, or question.
McGrail et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: